Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

Why It Matters

BAT offers a non‑pharmacologic tool that can augment guideline‑directed therapy and reduce costly hospital encounters for advanced heart‑failure patients, addressing an unmet clinical need.

Key Takeaways

• LVEF rose from 26.8% to 29.9% at six months
• 34% of patients improved NYHA class by at least one
• Hospitalizations dropped 14%–29% after Barostim implantation
• 33.6% received BAT off‑label, expanding real‑world use
• Survival benefit remains unproven, pending long‑term data

Pulse Analysis

Baroreflex activation therapy (BAT) uses the Barostim device to modulate autonomic tone, counteracting the sympathetic overdrive that drives heart‑failure progression. The recent REBALANCE registry, the largest post‑marketing cohort for BAT, enrolled 435 advanced HFrEF patients across 45 U.S. sites, many of whom were already on guideline‑directed medical therapy (GDMT) such as ARNIs and SGLT2 inhibitors. By delivering electrical signals to the carotid baroreceptors, BAT aims to restore baroreflex sensitivity, offering a non‑pharmacologic complement to existing drug regimens. Early adoption signals growing clinician confidence.

Six‑month follow‑up showed a statistically significant rise in mean left‑ventricular ejection fraction from 26.8 % to 29.9 % and a 34 % rate of NYHA class improvement, benefits that persisted through two years in a subset of patients. A parallel analysis of 1,533 implants from the COSMOS database reported 14 % fewer all‑cause hospitalizations, a 29 % decline in heart‑failure admissions, and a 27 % drop in HF‑related emergency visits, despite a modest increase in overall ED use. Notably, one‑third of the registry cohort received BAT off‑label, demonstrating efficacy beyond the strict BeAT‑HF criteria.

The data reinforce BAT’s role as a safe adjunct for patients who have exhausted pharmacologic and conventional device options, positioning it as a bridge to improve quality of life and functional capacity. As adoption expands, payers will scrutinize cost‑effectiveness, especially given the lack of definitive survival benefit to date. Ongoing trials and longer‑term registry follow‑up are expected to clarify mortality impact and identify subpopulations that derive the greatest advantage, potentially reshaping heart‑failure treatment algorithms and stimulating further investment in neuromodulation technologies.